Ginkgo Bioworks Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Ginkgo Bioworks Holdings, Inc. filed a Form 8-K dated August 9, 2023, under Item 2.02 to report the issuance of a press release regarding financial results for the second quarter ended June 30, 2023.
The filing identifies Ginkgo’s Class A common stock and warrants as listed on the NYSE under the symbols DNA and DNA.WS, respectively.
Financial results and key metrics
The filing text provided does not include the financial results press release or clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, bookings, or other operating metrics. Those details are referenced in Exhibit 99.1 but are not reproduced in the supplied filing text.
Material changes versus the prior comparable period
The filing does not provide sufficient information to determine changes from the second quarter of the prior year or from the immediately preceding quarter.
Guidance, outlook, risks, and unusual items
The filing does not include management guidance, outlook commentary, risk updates, contingencies, or unusual items. Any such information may appear in the referenced Exhibit 99.1 press release, which is not included in the supplied text.
Important facts to verify
- Obtain and review Exhibit 99.1 for the complete second-quarter financial results.
- Verify reported revenue, loss, adjusted metrics, cash flow, cash balance, debt, and liquidity.
- Compare the second-quarter results with the prior-year comparable period and first-quarter 2023.
- Review management’s full-year 2023 guidance and any revisions to operating or cash-use expectations.
- Check the press release for material risks, contingencies, non-GAAP reconciliations, and unusual transactions.